Primary or secondary antifungal prophylaxis in patients with hematological maligancies: efficacy and damage
Authors Gedik H, Şimşek F, Yildirmak T, Kantürk A, Arıca D, Aydın D, Demirel N, Yokuş O
Received 24 December 2013
Accepted for publication 19 February 2014
Published 28 April 2014 Volume 2014:10 Pages 305—312
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Habip Gedik,1 Funda Şimşek,1 Taner Yildirmak,1 Arzu Kantürk,1 Deniz Arica,2 Demet Aydin,2 Naciye Demirel,2 Osman Yokuş2
1Department of Infectious Diseases and Clinical Microbiology, 2Department of Hematology, Ministry of Health Okmeydani Training and Research Hospital, İstanbul, Turkey
Background: Patients with hematological malignancies often develop febrile neutropenia (FN) as a complication of cancer chemotherapy. Primary or secondary antifungal prophylaxis is recommended for patients with hematological malignancies to reduce the risk of invasive fungal infection (IFI). This study retrospectively evaluated the efficacy and potential harm of administration of primary and secondary antifungal prophylaxis to patients with hematological malignancies at one hospital.
Methods: All patients with hematological malignancies older than 14 years of age who had experienced at least one FN attack during chemotherapy while being treated at one hospital between November 2010 and November 2012 were retrospectively evaluated.
Results: A total of 282 FN episodes in 126 consecutive patients were examined during a 2-year study period. The mean patient age was 51.73±14.4 years (range: 17–82 years), and 66 patients were male. Primary prophylaxis with posaconazole was administered to 13 patients and systemic antifungal treatment under induction or consolidation chemotherapy to seven patients. Of 26 patients who received secondary antifungal prophylaxis with either oral voriconazole (n=17) or posaconazole (n=6) during 46 FN episodes, systemic antifungal therapy was administered in 16 of 38 episodes and three of eight episodes, respectively. Secondary antifungal prophylaxis with caspofungin was found effective in treating six FN episodes in three patients who had experienced at least two persistent candidemia attacks. The mortality rates associated with IFI were 9% in the first year, 2% in the second year, and 6% overall. The mortality rates associated with candidemia were 33% in the first
year, 22% in the second year, and 27% overall.
Conclusion: Primary antifungal prophylaxis should be administered to selected patients on the basis of consideration of efficacy, cost, and potential harm. Use of secondary prophylaxis may reduce systemic antifungal use and IFI frequency but may increase risk of colonization and infection with azole-resistant fungal strains.
Keywords: azole resistance, febrile neutropenia, hematological malignancy, invasive fungal infection, primary antifungal prophylaxis, secondary antifungal prophylaxis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]